| Lindsey Sutton, CCC-SLP | |
|
3160 N Arizona Ave, Chandler, AZ 85225-7122 | |
| (480) 699-4845 | |
| Not Available |
| Full Name | Lindsey Sutton |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 3160 N Arizona Ave, Chandler, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083327027 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | SLP12058 (Arizona) | Primary |
| Provider Name | Advanced Neurologic Rehabilitation |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1922482017 PECOS PAC ID: 5395055859 Enrollment ID: O20151112001859 |
News Archive
What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.
In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.
The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners.
Bristol-Myers Squibb and AstraZeneca have announced a collaboration to develop and commercialize two investigational compounds being studied for the treatment of Type 2 diabetes. Both compounds were discovered by Bristol-Myers Squibb.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Lindsey Sutton, CCC-SLP 1051 N Quail, Mesa, AZ 85205-5224 Ph: (480) 406-5911 | Lindsey Sutton, CCC-SLP 3160 N Arizona Ave, Chandler, AZ 85225-7122 Ph: (480) 699-4845 |
News Archive
What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.
In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.
The ovarian cancer market is highly active with several promising candidates having reached the late stages of development. Three PARP inhibitors, Lynparza (AstraZeneca), niraparib (Tesaro) and rucaparib (Clovis Oncology), which induce cell death in mutated [BRCA-deficient] cancer cells, have been identified by Datamonitor Healthcare as front runners.
Bristol-Myers Squibb and AstraZeneca have announced a collaboration to develop and commercialize two investigational compounds being studied for the treatment of Type 2 diabetes. Both compounds were discovered by Bristol-Myers Squibb.
› Verified 1 days ago
Ms. Heather Marie Liu, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 6543 S Teresa Dr, Chandler, AZ 85249 Phone: 480-329-7600 | |
Allison Dawn Smith, MS CCC SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 815 E Warner Rd, Suite 106, Chandler, AZ 85225 Phone: 480-963-5800 Fax: 480-963-5805 | |
Miss Demaurice Jiana Basile, M.S., CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Frye Rd, Chandler, AZ 85224 Phone: 480-812-7000 | |
Alicia Rowlett, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3400 N Alma School Rd Apt 2034, Chandler, AZ 85224 Phone: 719-671-7172 | |
Gail Cisneros, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 1525 W Frye Rd, Chandler, AZ 85224 Phone: 480-812-7000 | |
Gabrielle Christine Goldsmith, MS CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 964 E Cherry Hills Dr, Chandler, AZ 85249 Phone: 509-217-3367 | |
Lauren Mead, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 3160 N Arizona Ave Ste 105, Chandler, AZ 85225 Phone: 480-365-9981 |